Document is current
Any future updates will be listed below
-
Authors
Hanson, Kent A. https://orcid.org/0000-0002-7201-3324
Austin, Jenny https://orcid.org/0000-0003-4297-6290
Clayton, Nicola https://orcid.org/0009-0006-1895-6475
Anderson, Peter https://orcid.org/0000-0002-2171-8228
Vano-Galvan, Sergio https://orcid.org/0000-0003-2773-7494
Marwaha, Simran https://orcid.org/0000-0003-0380-0372
Kurosky, Samantha K. https://orcid.org/0000-0003-2392-8111
Lejeune, Alexandre
Piercy, James https://orcid.org/0000-0001-7015-1021
Law, Ernest H. https://orcid.org/0000-0002-6111-8008
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 24 March 2025
Accepted: 30 June 2025
First Online: 21 July 2025
Declarations
:
: KA Hanson was a paid consultant to Pfizer during the period in which the work for this manuscript was conducted. The author is no longer affiliated with the company. J Austin, P Anderson, S Marwaha, and J Piercy are employees of Adelphi Real World. N Clayton has no competing interests. S Vano-Galvan reports consulting fees and payment/honoraria from Pfizer and Lilly. SK Kurosky, A Lejeune, and EH Law are employees of and hold stock or stock options in Pfizer.
: Data were collected according to European Pharmaceutical Marketing Research Association guidelines [], and the DSP protocol (21-ADRW-122) was submitted to the Western Institutional Review Board and was granted an exemption. Data were collected in full accordance with relevant legislation at the time. The study was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. The submission does not include personal details or images that may lead to the identification of participants.
